HSBC Knock-Out NVO/ DE000HS41G06 /
10/06/2024 08:22:03 | Chg.+0.17 | Bid22:00:10 | Ask22:00:10 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
3.64EUR | +4.90% | - Bid Size: - |
- Ask Size: - |
Novo Nordisk | 105.379 USD | 31/12/2078 | Call |
GlobeNewswire
10/06
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire
31/05
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire
30/05
Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire
15/05
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
GlobeNewswire
14/05
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...
GlobeNewswire
09/05
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
07/05
Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference
GlobeNewswire
22/04
Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to...
GlobeNewswire
22/04
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire
22/04
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire
11/04
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
GlobeNewswire
02/04
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
28/03
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategi...
GlobeNewswire
27/03
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completio...
GlobeNewswire
25/03
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the ...
GlobeNewswire
18/03
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ ...